ArticleInternational journal of nanomedicine2025
Multi-Response Au-Nanohybrid Composite Triggered NIR-Light for Effective Anti-Tumor Therapy in Animal Model.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The therapeutic efficacy of nanomedicine in oncology is predicated on its capacity to enhance drug uptake by cells and control drug release. While targeted nanomedicines are highly regarded for their potential, they are not spared from issues of colloidal instability and uncontrolled drug release. Methods: The hybrid system (Au@SiO Results: Under NIR irradiation, the nanoparticles exhibited excellent photothermal stability and sustained temperature elevation. In vitro studies demonstrated that the nanoparticles possessed good biocompatibility (cell viability exceeding 90%) and colloidal stability (7 days). The loading efficiency of DOX was enhanced to 65.9%, with sustained release characteristics. Furthermore, Au@SiO Conclusion: This nanohybrid system represents a promising strategy for improving the efficacy of chemotherapy and reducing toxicity in cancer treatment. It enhances drug enrichment and release in tumor tissues while minimizing the impact on normal tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.